Table 3.
Vectors | Synthetic inner cores | Payloads | Targeting mechanisms/sites | Indications | References |
---|---|---|---|---|---|
RBC membrane | MSNs | Dox | Laser-activated tumor-specific accumulation | Breast cancer | 43 |
PLGA | RAP | EPR effect in atherosclerotic lesions | Atherosclerosis | 18 | |
Nanocrystals | DTX | Tumor-targeting ligands | Glioma | 47 | |
Cationic liposomes | AmB | Specific affinity between pathogenic fungi and erythrocytes | Fungal infection | 53 | |
CCM | Aluminum phosphate nanoparticles | CpG | Lymph node-resident APCs | Melanoma | 14 |
Calcium pyrophosphate nanoparticles | - | Targeting to dendritic cells | Melanoma | 75 | |
Porous Au@Rh | ICG | Homologous targeting | Breast cancer | 78 | |
PLGA | ICG | Homologous targeting | Breast cancer | 79 | |
Au nanostars | Dox | Homologous targeting | Melanoma | 81 | |
Boron nitride nanotubes | Dox | Homologous targeting | Glioblastoma | 83 | |
MSNs | Dox | Homologous targeting | Prostate cancer | 85 | |
Gelatin nanoparticles | Cisplatin | Homologous targeting | Head and neck squamous cell carcinoma | 86 | |
Neutrophil membrane | Polycaprolactonepoly(ethylene glycol) nanoparticles | Sparfloxacin | Inflammatory targeting | Inflammation | 15 |
PLGA | - | Binding to immunoregulatory molecules | Rheumatoid arthritis | 87 | |
Cationic liposome | MTX | Targeting to macrophages | Inflamed skeletal muscle; ischemic heart | 92 | |
Poly(latic-co-glycolic acid) nanoparticles | Carfilzomib | CTC- and niche-targeting | Cancer metastasis | 98 | |
NK cell membrane | Liposomes | Dox | Targeting tumor cells with the help of NK cell markers | Breast cancer | 23 |
mPEG-PLGA nanoparticles | TCPP | Binding of tumor-targeting proteins | Primary and abscopal tumor | 88 | |
Carboxylate terminated PLGA | Gd lipid | Tumor-homing natural killer cell membrane | Tumor imaging | 16 | |
Macrophage membrane | UCNPs | - | Cell-cell adhesion for cancer targeting | Breast cancer | 103 |
Liposome | Emtansine |
α4β1 integrin-VCAM-1 interactions |
Lung metastasis of breast cancer | 89 | |
Hollow bismuth selenide nanoparticles | Quercetin | CCL2/CCR2- mediated recruitment | Lung metastasis of breast cancer | 106 | |
PEGylation nanoparticle | PTX | IGF1R targeting ligand | Breast cancer | 17 | |
Platelet membrane | DSPE-PEG polymers | Gevokizumab | Infarct-homing ability of platelets | Acute myocardial infarction | 110 |
Porous metal-organic framework nanoparticles | siRNA | Tumor-targeting capability of platelets | Breast cancer | 19 | |
Myeloid-derived suppressor cell membrane | Iron oxide magnetic nanoparticles | - | MDSC with high affinity to melanoma | Melanoma | 111 |
Platelet-RBC hybrid membrane | Liposome | Chlorin e6 and tirapazamine | Biomimetic surface molecules | Melanoma and lung metastasis | 112 |
RBC-cancer hybrid membrane | CuS nanoparticles | Dox | Homologous targeting | Melanoma | 114 |
RBC-cancer hybrid membrane | - | Melanin nanoparticles | Homologous targeting | Breast cancer | 317 |
Macrophage-derive Exo | - | SPION and Cur | Neuropilin-1-targeted peptide | Glioma | 134 |
MSCs-derived Exo | EGNPs | - | Binding of glucose and GLUT-1 glucose transporter | CT imaging of acute striatal stroke | 136 |
Normal fibroblast-like mesenchymal cell-derived Exo | - | siRNA or shRNA | RNA payloads specific to oncogenic KrasG12D | Pancreatic cancer | 141 |
Exo | PEGylated nanoparticles | V2C QDs | RGD-targeting tumor cells and TAT peptides targeting nucleus | Breast cancer | 144 |
Tumor-derived Exo | PEG-PCL NPs | PTX-S-LA and CuB | High affinity between CCM and homotypic Exo membrane | Breast cancer metastasis | 152 |
Tumor cell-derived Exo | - | mRNAs | Targeting peptides | Glioma | 153 |
Dendritic cell-derived Exo | - | siRNA | Lamp2b fused to the neuron-specific RVG peptide | Alzheimer’s disease | 160 |
Macrophages-derived Exo | - | Catalase | Surface adhesion proteins | Parkinson’s disease | 159 |
Exo | - | Biologically active proteins | Floxed reporter cells | Brain diseases | 163 |
Exo | - | Oligonucleotides drugs | Muscle-targeting peptide | Dystrophin deficiency | 165 |
Tumor cell-derived MVs | - | MTX | Attracting neutrophils | CCA | 173 |
DCs-derived MVs | - | PTX | Aptamer AS1411 targeting nucleolin | Breast cancer | 177 |
CCM-derived MVs | Extremely small-sized iron oxide nanoparticles | Glucose oxidase | Homologous and RGD-targeting | Hepatocellular carcinoma | 179 |
SV40-VNPs | - | QDs and Hirulog | Targeting peptides | Atherosclerotic plaques | 200 |
HBc VNPs | - | ICG | RGD-targeting tumor cells | Glioblastoma | 204 |
AAV | - | VEGF | Targeting to myocardium | Ischemic myocardial disease | 208 |
HBc VNPs | - | Dox | Integrin αvβ3-mediated targeting | Glioblastoma | 215 |
Dd VNPs | - | Dox or cap analog | Targeting liver cancer cells | Hepatocellular carcinoma | 217 |
RVG-hybrids VNPs | QDs and pH-responsive dendrimers | Dox and Pb | RVG-guided and hierarchical targeting | Orthotopic brain tumor | 221 |
FMD VNPs | - | Dox | RGD-targeting tumor cells | Carcinoma of the uterine cervix | 224 |
Qβ VNPs | - | RNAi | Peptide targeting to tumor cells | Glioblastoma | 235 |
Qβ VNPs | - | Azithromycin | Ligands targeting lung-resident macrophages | Pulmonary infections | 244 |
P22 VNPs | - | Cas9 and a single-guide RNA | Targeting to specific cell | Genetic diseases | 247 |
MS2 VNPs | - | mRNA | Inducing specific immunity | Prostate cancer | 254 |
TMV VNPs | - | PhenPt | Tumor-homing ability of AR engineering | Triple-negative breast cancer | 263 |
TMV VNPs | - | Silencer GFP siRNA | Passive targeting | Hepatoma | 270 |
CPMVVNPs | - | MTO | Targeting to cerebral endothelial cells | Glioblastoma | 284 |